AEROGEN PHARMA LIMITED
๐ฎ๐ชIreland
VentaProst in Subjects With COVID-19 Requiring Mechanical Ventilation
Phase 2
Completed
- Conditions
- COVID-19
- Interventions
- First Posted Date
- 2020-06-30
- Last Posted Date
- 2021-08-05
- Lead Sponsor
- Aerogen Pharma Limited
- Target Recruit Count
- 11
- Registration Number
- NCT04452669
- Locations
- ๐บ๐ธ
Ohio State University, Columbus, Ohio, United States
A Dose-Ranging Study to Determine the Efficacy, Safety and Tolerability of AeroFact
Phase 2
Completed
- Conditions
- Respiratory Distress Syndrome in Premature Infant
- Interventions
- Other: nCPAPDrug: AeroFact
- First Posted Date
- 2019-05-31
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Aerogen Pharma Limited
- Target Recruit Count
- 261
- Registration Number
- NCT03969992
- Locations
- ๐บ๐ธ
University of Illinois, Chicago, Illinois, United States
๐บ๐ธUniversity of Washington, Seattle, Washington, United States
๐บ๐ธChildren's Hospital of San Antonio (CHofSA), San Antonio, Texas, United States
VentaProst Versus Conventionally-Administered Aerosolized Epoprostenol in Patients Undergoing Cardiac Surgery With CPB
Phase 2
Completed
- Conditions
- Pulmonary Hypertension
- Interventions
- Combination Product: VentaProst
- First Posted Date
- 2017-04-21
- Last Posted Date
- 2019-05-31
- Lead Sponsor
- Aerogen Pharma Limited
- Target Recruit Count
- 15
- Registration Number
- NCT03122730
- Locations
- ๐บ๐ธ
Stanford University Medical Center, Stanford, California, United States
๐บ๐ธTufts Medical Center, Boston, Massachusetts, United States
๐บ๐ธRush University Medical Center, Chicago, Illinois, United States
ยฉ Copyright 2025. All Rights Reserved by MedPath